ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary ...
Pharvaris has announced the start of enrollment in CHAPTER-3, a Phase 3 study assessing the efficacy of deucrictibant for preventing hereditary angioedema (HAE) attacks, with topline results expected ...
The last three decades have seen an often acrimonious debate about the effects of the military use of herbicides in Vietnam and, in particular, the potential adverse long-term health effects on those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results